

BOOKLET OF PARTICIPANTS

UNDER THE AUSPICES OF:



OCTOBER 28-30, 2015

PANCREATIC CANCER SYMPOSIUM

PALAIS DU PHARO
MARSEILLE, FRANCE
WWW.PCS-2015.COM

ORGANISING COMMITTEE:

FRÉDÉRIC ANDRÉ, CRO2, MARSEILLE
LAURENT BARTHOLIN, CRCL, LYON
CORINNE BOUSQUET, CRCT, TOULOUSE
JÉRÔME CROS, HÔPITAL BEAUJON, CLICHY
ÉRIC MAS, CRO2, MARSEILLE
RICHARD TOMASINI, CRCM, MARSEILLE
STÉPHANIE TRUANT, CHRU, LILLE
SOPHIE VASSEUR, CRCM, MARSEILLE

FACULTY & SPEAKERS

FACULTY

S. Antoun , France	E. Hessmann , Germany
N. Bardeesy , USA	M. Hidalgo , Spain
E. Costello , United Kingdom	F. Novelli , Italy
O. Farges , France	K. Olive , USA
A. Kimmelman , USA	D. Saur , Germany
M. Korc , USA	D. Tuveson , USA
P. Hammel , France	M. Vander Heiden , USA

SPEAKERS

S. Antoun , France	S. Kugel , USA
N. Bardeesy , USA	L. T. N. Lenk , Germany
P. Chiao , USA	J. Morton , United Kingdom
J. Cros , France	V. Moutardier , France
C. Bousquet , France	C. Neuzillet , France
L. Buscail , France	R. Nicolle , France
P. Cappello , Italy	F. Novelli , Italy
P. Cordelier , France	K. Olive , USA
E. Costello , United Kingdom	D. Pietrasz , France
N. Chuvin , France	J-L. Raoul , France
S. Dougan , USA	D. Saur , Germany
O. Farges , France	P. Sancho , United Kingdom
F. Guillaumond , France	C. Steele , United Kingdom
J. Guillermet-Guibert , France	G. Su , USA
P. Hammel , France	R. Tomasini , France
E. Hessmann , Germany	D. Tuveson , USA
M. Hidalgo , Spain	M. Vander Heiden , USA
N. Kalaany , USA	S. Vasseur , France
A. Kimmelman , USA	B. Westphalen , Germany
M. Korc , USA	

SCIENTIFIC PROGRAM













WEDNESDAY OCTOBER 28TH, 2015

17.00-18.00	 Welcome participant
18.00-18.15	 OPENING OF THE SYMPOSIUM by <i>L. Buscail</i> , President of the AFRCP, FR
18.15-19.00	 OPENING KEYNOTE LECTURE: <i>Modeling and manipulating pancreatic cancer</i> by <i>D. Tuveson</i> , Cold Spring Harbor Laboratory, New York, US
19.00-19.15	 WELCOME TO MARSEILLE by <i>V. Boyer</i> , Deputy Mayor of Marseille, FR
19.15-20.00	 Local wine and cheese

THURSDAY OCTOBER 29TH, 2015













SESSION I: IMPACT OF MICROENVIRONMENT ON PANCREATIC CANCER

Chairs: D. Tuveson & K. Olive

- 09.00-09.45  **KEYNOTE LECTURE: Modelling and targeting the microenvironment of pancreatic cancer**
by D. Saur, Technical University of Munich, DE
- 09.45-10.10  **Inflammation driven nuclear complexes in pancreatic carcinogenesis and PDAC progression** by E. Hessmann, University Medical Center Göttingen, DE
- 10.10-10.20  **Sleep is the enemy: cellular dormancy and cancer stem cell properties are influenced by hepatic alterations in disseminated pancreatic ductal epithelial cells** by L. T. N. Lenk, UKSH Kiel, DE - SELECTED PRESENTATION A21
- 10.20-10.30  **Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumor chemoresistance and metastasis** by C. Bousquet, INSERM U1037, Toulouse, FR - SELECTED PRESENTATION A17
- 10.30-11.00  Break
Chairs: É. Mas & F. Novelli
- 11.00-11.25  **α-enolase (ENO1) as therapeutic and immunological target in pancreatic cancer** by F. Novelli, University of Turin, IT
- 11.25-11.35  **IL-17 promotes pancreatic cancer progression and limits the anti-tumor responses** by P. Cappello, University of Turin, IT - SELECTED PRESENTATION A6
- 11.35-11.45  **Development of immune based therapies for pancreatic cancer** by S. Dougan, Dana-Farber Cancer Institute, Boston, US - SELECTED PRESENTATION A3
- 11.45-11.55  **CXCR2 inhibition profoundly suppresses metastases and improves immunotherapy in pancreatic ductal adenocarcinoma** by C. Steele, Beatson Institute for Cancer Research, Glasgow, UK - SELECTED PRESENTATION A2
- 11.55-12.05  **Impact of the intra-tumoral microenvironment and the epithelial cells crosstalk in pancreatic carcinogenesis** by R. Tomasini, INSERM U1068, Marseille, FR - SELECTED PRESENTATION A7
- 12.05-12.30  **Panel discussion**
- 12.30-14.30  **Posters session A and lunch**

SESSION II: METABOLISM














Chairs: M. Vander Heiden & N. Bardeesy

- 14.30-15.15  **KEYNOTE LECTURE: Role of metabolism in pancreatic cancer**
by M. Vander Heiden, MIT, Cambridge, Massachusetts, US
- 15.15-15.40  **Identifying metabolic dependencies in pancreatic cancer**
by A. Kimmelman, Dana-Farber Cancer Institute, Boston, US
- 15.40-15.50  **Pancreatic cancer stem cells are characterized by a distinct metabolic phenotype with limited plasticity** by P. Sancho, Barts Cancer Institute, London, UK - SELECTED PRESENTATION A35
- 15.50-16.00  **Metabolism reprogramming of pancreatic adenocarcinoma: when collagen becomes a supply center for epithelial tumour cells** by S. Vasseur, INSERM U1068, Marseille, FR - SELECTED PRESENTATION A34
- 16.00-16.30  Break
Chairs: A. Kimmelman & S. Vasseur
- 16.30-16.55  **Impact of muscle mass depletion in patients with advanced cancer: how to improve muscle protein anabolism?**
by S. Antoun, IGR, Paris, FR
- 16.55-17.05  **Identifying metabolic dependencies in obesity-associated pancreatic cancer** by N. Kalaany, Harvard Medical School / Boston Children's Hospital, Boston US - SELECTED PRESENTATION A31
- 17.05-17.15  **Pancreatic ductal adenocarcinoma lipid signature: identification and characterization of crucial therapeutic metabolic-targets in tumor progression** by F. Guillaumond, INSERM U1068 CRCM, Marseille, FR - SELECTED PRESENTATION A36
- 17.15-17.25  **Lessons learned from first-in-man gene therapy clinical trial for pancreatic cancer: targeting tumor metabolism to tackle chemoresistance** by P. Cordelier, INSERM U1037, Toulouse, FR - SELECTED PRESENTATION A33
- 17.25-17.35  **Exploring mTOR-dependent vulnerabilities in pancreatic cancer** by J. Morton, CRUK Beatson Institute, Glasgow, UK - SELECTED PRESENTATION A30
- 17.35-18.00  **Panel discussion**
- 19.00  Gala dinner at Restaurant La Nautique

FRIDAY OCTOBER 30TH, 2015













SESSION III: PRECLINICAL AND CLINICAL ADVANCES

Chairs: M. Korc & A. Sadanandam

- 08.30-09.15  **KEYNOTE LECTURE** by *N. Bardeesy*,
General Hospital and Harvard Medical School, Boston, US
- 09.15-09.40  **News in the treatment of advanced pancreatic cancer (PC)**
by *P. Hammel*, Hôpital Beaujon, Clichy, FR
- 09.40-09.50  **Genomic profiling of patient-derived xenografts with pancreatic adenocarcinoma: evaluation of the pacaomics trial pilot phase**
by *R. Nicolle*, Ligue Nationale contre le Cancer, Paris, FR -
SELECTED PRESENTATION B55
- 09.50-10.00  **Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment: a potential predictive biomarker of response to MEKi alone or in combination with PI3Ki-mTOR inhibitors in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models**
by *C. Neuzillet*, Henri Mondor University Hospital, Créteil, FR -
SELECTED PRESENTATION B47
- 10.00-10.20  Break
- Chairs: E. Costello & P. Hammel
- 10.20-10.45  **Causes and consequences of aberrant TGF-beta signaling in pancreatic cancer** by *M. Korc*, IU Simon Cancer Center
Indiana University School of Medicine, Indianapolis, US
- 10.45-11.10  **Management of pancreatic cancer in France, based on the analysis of the national administrative database**
by *O. Farges*, National analysis of management,
Beaujon Hospital, Clichy, FR
- 11.10-11.20  **Prognostic value of circulating tumoral DNA in patients with advanced pancreatic adenocarcinoma** by *D. Pietrasz*, Paris
Descartes University, Paris, FR - SELECTED PRESENTATION B65
- 11.20-11.30  **High c-Met expression defines a subset of pancreatic adenocarcinoma with poor prognosis following surgical resection: comparison of three c-Met scoring methods, exploration of underlying mechanisms of c-Met overexpression, and transcriptomic characterization of high c-Met tumors** by *J. Cros*,
Beaujon Hospital, Clichy, FR - SELECTED PRESENTATION B58
- 11.30-11.45  **SYMPOSIUM** 
Medical treatment of metastatic pancreatic adenocarcinoma: evolutions? by *J-L. Raoul*, IPC, Marseille, FR
- 11.45-12.15  **Panel discussion**
- 12.15-13.45  **Posters session B and lunch**

SESSION IV: CANCER CELL SIGNALS AND SIGNALING

Chairs: M. Hidalgo & L. Bartholin

- 13.45-14.30  **KEYNOTE LECTURE: Integrating mouse models in PDAC treatment** by *M. Hidalgo*, National Center for Investigation
in Oncology (CNIO), Madrid, ES
- 14.30-14.55  **Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus** by *E. Costello*, National Institute
for Health Research, Liverpool, UK
- 14.55-15.05  **Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer** by *S. Kugel*, Massachusetts General
Hospital / Harvard Medical School, Boston, US - SELECTED
PRESENTATION B80
- 15.05-15.15  **Target undruggable mutant kras in mouse model of pancreatic ductal adenocarcinoma** by *P. Chiao*, The University of Texas
N. D. Anderson Cancer Center, Houston, US - SELECTED
PRESENTATION B88
- 15.15-15.35  Break
- Chairs: D. Saur & J. Iovanna
- 15.35-16.00  **Paracrine signaling in pancreatic ductal adenocarcinoma**
by *K. Olive*, Columbia University Medical Center, New York, US
- 16.00-16.10  **The unique roles of activin and Notch4 signaling pathways in the development of intraductal papillary mucinous neoplasm** by *G. Su*, Colombia University, New York, US -
SELECTED PRESENTATION B92
- 16.10-16.20  **Targeted activation of TGFβ signaling in pancreatic epithelial cells accelerates kras-induced tumorigenesis** by *N. Chuvp*,
CRC Lyon, FR - SELECTED PRESENTATION B89
- 16.20-16.30  **Dclk1 is a novel kras effector and marks pancreatic stem and cancer initiating cells** by *B. Westphalen*, Ludwig-Maximilians
University Munich, DE - SELECTED PRESENTATION B74
- 16.30-16.40  **Isoform-specific PI3K-induced signalling differs along pancreatic cancerogenesis but controls the induction of other signalling pathways** by *J. Guillermet-Guibert*, INSERM U1037, Toulouse, FR -
SELECTED PRESENTATION B79
- 16.40-17.00  **Panel discussion**
- 17.00  **Awards ceremony**
Closing remarks by *C. Bousquet*, CRTC Toulouse, FR
& *V. Moutardier*, AP-HM Hôpital Nord, Marseille, FR